Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,231 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,680 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05660473 | Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia | recruiting | Phase 2 | 100 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 1, 2025 | clinicaltrials |
| NCT06762769 | Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma(MODIFY) | recruiting | Phase 2 | 63 | University College, LondonOTHER | 1 |
| Aug 1, 2025 |
| clinicaltrials |
| NCT04961515 | Orelabrutinib, Sintilimab and Temozolomide in Relapsed or Refractory Central Nervous System Lymphoma | recruiting | Phase 2 | 19 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jul 31, 2025 | clinicaltrials |
| NCT05820126 | Cold Versus Room Temperature Storage of Platelets for Bleeding in Hematologic Malignancy - a Pilot Trial(CoVeRTS-HM) | recruiting | Phase 2 | 50 | Ottawa Hospital Research InstituteOTHER | 1 | Jul 31, 2025 | clinicaltrials |
| NCT06058572 | Effect of Rifaximin on Gut Bacterial Flora Post Stem Cell Transplant in Patients With Acute Leukemia | recruiting | Phase 2 | 166 | Tata Memorial CentreOTHER | 1 | Jul 31, 2025 | clinicaltrials |
| NCT07097207 | Efficacy and Safety of CD19CD20-CAR.p40-T in B-cell Lymphoma(CAR-T) | recruiting | Phase 1 / Phase 2 | 20 | Shenzhen University General HospitalOTHER | 1 | Jul 31, 2025 | clinicaltrials |
| NCT06838832 | Novel Allogenic CD19-targeting CAR-γδT Cell Therapy (QH103E) in r/r NHL | recruiting | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT07094477 | Study of Targeted CD22/CD19 CAR-T Therapy for First-line Consolidation of B-cell Lymphoma | active not recruiting | Phase 2 | 50 | Daihong LiuOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT07090954 | A Study of GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participants With Multiple Myeloma | not yet recruiting | Phase 1 / Phase 2 | 32 | Genrix (Shanghai) Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 29, 2025 | clinicaltrials |
| NCT06045910 | A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies | recruiting | Phase 1 / Phase 2 | 84 | Cancer Research UKOTHER | 1 | Jul 28, 2025 | clinicaltrials |
| NCT07078591 | Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AML | recruiting | Phase 2 | 50 | Beijing 302 HospitalOTHER | 1 | Jul 28, 2025 | clinicaltrials |
| NCT05182385 | Venetoclax in Addition to Blinatumomab in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) | active not recruiting | Phase 1 / Phase 2 | 30 | Goethe UniversityOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT06984536 | Reduced ATG Plus Mini PTCy for GVHD Prophylaxis in Haplo-SCT | recruiting | Phase 2 | 40 | Peking University People's HospitalOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT06651853 | Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL | recruiting | Phase 2 | 22 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT07079423 | Teclistamab in Newly Diagnosed Mayo Stage IIIB AL Amyloidosis | recruiting | Phase 2 | 35 | Peking Union Medical College HospitalOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT07081607 | Golidocitinib With Azacitidine and Chidamide in Patients With Peripheral T-cell Lymphoma. | not yet recruiting | Phase 2 | 30 | Ruijin HospitalOTHER | 0 | Jul 23, 2025 | clinicaltrials |
| NCT04052880 | Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM | active not recruiting | Phase 2 | 17 | Larysa SanchezOTHER | 1 | Jul 20, 2025 | clinicaltrials |
| NCT07072494 | CD19 CAR-T Cell Infusion as Consolidation Therapy in Adolescent and Adult Patients With Acute B-ALL Ineligible for Allogeneic HSCT: A Clinical Study | recruiting | Phase 1 / Phase 2 | 30 | Zhujiang HospitalOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT06220097 | Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T Therapies | active not recruiting | Phase 2 | 28 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 17, 2025 | clinicaltrials |
| NCT07069933 | Repurposing Itraconazole as an Adjuvant Therapy in Treatment of Patients With Acute Myeloid Leukemia: Is it a Hopeful Avenue for Enhancing Treatment Options? | not yet recruiting | Phase 2 | 50 | Mansoura UniversityOTHER | 1 | Jul 17, 2025 | clinicaltrials |
| NCT07070934 | CAR-T vs. Auto-SCT: Which Works Better for New Myeloma Patients?(ASCTvsCAR-T) | not yet recruiting | Phase 2 | 60 | Xuzhou Medical UniversityOTHER | 0 | Jul 17, 2025 | clinicaltrials |
| NCT03971799 | Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia | active not recruiting | Phase 1 / Phase 2 | 52 | Center for International Blood and Marrow Transplant ResearchNETWORK | 1 | Jul 14, 2025 | clinicaltrials |
| NCT06682130 | Glofitamab Bridging ASCT for Patients With Relapsed or Refractory DLBCL(ASCT DLBCL) | recruiting | Phase 2 | 40 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jul 14, 2025 | clinicaltrials |
| NCT07059156 | Multicenter Study of Combined Chemotherapy and Transplantation for Adult ALL | recruiting | Phase 2 / Phase 3 | 50 | Shanxi Bethune HospitalOTHER | 1 | Jul 10, 2025 | clinicaltrials |
| NCT07028086 | VAM in Secondary AML, AML With Extramedullary Involvement, and Myeloid Sarcoma | recruiting | Phase 2 | 48 | Ruijin HospitalOTHER | 1 | Jul 9, 2025 | clinicaltrials |
| NCT07055724 | Study of Eque-cel CAR-T Therapy in Newly Diagnosed Severe AL Amyloidosis | not yet recruiting | Phase 2 | 17 | Nanjing IASO Biotechnology Co., Ltd.INDUSTRY | 0 | Jul 9, 2025 | clinicaltrials |
| NCT05123131 | Isa-RVD Study in Patients With Newly Diagnosed Multiple Myeloma(Isa-RVD) | active not recruiting | Phase 2 | 54 | Cancer Trials IrelandNETWORK | 2 | Jul 8, 2025 | clinicaltrials |
| NCT06409936 | PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML(PEARL) | recruiting | Phase 2 | 160 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Jul 8, 2025 | clinicaltrials |
| NCT04851717 | Investigation of Remimazolam in Children Undergoing Sedation for Medical Procedures | active not recruiting | Phase 2 / Phase 3 | 100 | Acacia Pharma LtdINDUSTRY | 2 | Jul 1, 2025 | clinicaltrials |
| NCT06199557 | A Study to Investigate Treatment of HU and VPA, or 6-MP and VPA in Unfit AML/HR-MDS Patients(HUVAMER) | recruiting | Phase 1 / Phase 2 | 48 | Haukeland University HospitalOTHER | 1 | Jun 29, 2025 | clinicaltrials |
| NCT07032532 | Assessing An Oral JAK1 Inhibitor, Golidocitinib, in Patients Who Have Newly Diagnosed Peripheral T-Cell Lymphoma (JACKPOT23) | not yet recruiting | Phase 2 | 35 | Sun Yat-sen UniversityOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT07008885 | BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B-ALL | recruiting | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Jun 25, 2025 | clinicaltrials |
| NCT07009002 | BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma | recruiting | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Jun 25, 2025 | clinicaltrials |
| NCT07036250 | Clinical Study of U32 in Patients With Acute Myeloid Leukemia | recruiting | Phase 1 / Phase 2 | 20 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdINDUSTRY | 1 | Jun 25, 2025 | clinicaltrials |
| NCT07034508 | A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1 | not yet recruiting | Phase 2 | 134 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jun 24, 2025 | clinicaltrials |
| NCT07031700 | A Multicenter, Single-Arm, Open-Label, Phase II Trial of Mosunetuzumab in Combination With Tislelizumab for r/r FL | not yet recruiting | Phase 2 | 22 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Jun 22, 2025 | clinicaltrials |
| NCT07032129 | Sequential CAR-T Cells Targeting BCMA/GPRC5D in Patients With Relapsed/ Refractory Multiple Myeloma(BAH2573) | recruiting | Phase 1 / Phase 2 | 60 | Essen BiotechOTHER | 1 | Jun 22, 2025 | clinicaltrials |
| NCT07028073 | A New Treatment of Newly Diagnosed KIT Mutation CBF-Acute Myeloid Leukemia | recruiting | Phase 1 / Phase 2 | 78 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 19, 2025 | clinicaltrials |
| NCT03817320 | PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma | active not recruiting | Phase 1 / Phase 2 | 24 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 2 | Jun 17, 2025 | clinicaltrials |
| NCT06700798 | Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL： A Randomized, Open Phase II Trial | recruiting | Phase 2 | 90 | Fei LiOTHER | 1 | Jun 17, 2025 | clinicaltrials |
| NCT01985061 | Evaluation of 3 Different Doses of IV Busulfan(AAA) | active not recruiting | Phase 2 | 177 | Institut Paoli-CalmettesOTHER | 1 | Jun 15, 2025 | clinicaltrials |
| NCT07021677 | Use of a New Medicine "Daratumumab" to Treat Left-over Cancer in a Blood Cancer Called "T Acute Lymphoblastic Leukemia"(DARA_T_ALL) | recruiting | Phase 2 | 18 | Tata Memorial CentreOTHER | 1 | Jun 15, 2025 | clinicaltrials |
| NCT07022223 | Orelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone Lymphoma | recruiting | Phase 2 | 51 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jun 15, 2025 | clinicaltrials |
| NCT05253495 | Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma(RADICAL) | recruiting | Phase 2 | 80 | New York Medical CollegeOTHER | 1 | Jun 13, 2025 | clinicaltrials |
| NCT06862323 | Time Restricted Eating in Haematological Malignancies | not yet recruiting | Phase 2 | 75 | British Columbia Cancer AgencyOTHER | 1 | Jun 13, 2025 | clinicaltrials |
| NCT07020260 | The PACMAN-Hu19 Trial: a Study of the Safety and Feasibility of Locally Produced, CD19-targeted and Human CAR T-cell Therapy in Children and Young Adults With Relapsed or Refractory B-cell Malignancies(PACMAN) | not yet recruiting | Phase 1 / Phase 2 | 18 | Princess Maxima Center for Pediatric OncologyOTHER | 1 | Jun 13, 2025 | clinicaltrials |
| NCT04687176 | Frontline Oral Arsenic Trioxide for APL | recruiting | Phase 2 | 100 | The University of Hong KongOTHER | 2 | Jun 12, 2025 | clinicaltrials |
| NCT07014943 | High-Dose Gemcitabine, Busulfan, and Thiotepa Followed by ASCT in Primary Central Nervous System Lymphoma | recruiting | Phase 2 | 34 | Sichuan UniversityOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT06778187 | Oral-ATO for TP53-mutated Myeloid Malignancies | recruiting | Phase 2 | 30 | The University of Hong KongOTHER | 1 | Jun 10, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Aug 1, 2025source: clinicaltrials